Betta Pharmaceuticals Co., Ltd.

Betta Pharmaceuticals Co., Ltd. saw a significant stock decline on June 16, 2026, reaching an intraday low. Over the past year, the company has underperformed compared to the China Shanghai Composite. Financially, it has a market capitalization of CNY 20,232 million and a high price-to-earnings ratio, indicating valuation concerns.

Betta Pharmaceuticals Co., Ltd. saw a significant intraday increase on June 11, 2026, contrasting with a slight decline in the China Shanghai Composite. While the company has gained notably in the short term, it has faced a decline over the past year, highlighting ongoing challenges in the sector.

Betta Pharmaceuticals Co., Ltd. has experienced notable stock activity, achieving a 4.58% increase on June 9, 2026. The company has shown a year-to-date gain of 9.55%, despite a 19.03% decline over the past year. Its market capitalization is CNY 20,232 million, classifying it as a large-cap firm.

Betta Pharmaceuticals Co., Ltd. faced a significant stock decline on June 2, 2026, amid ongoing market challenges. Over the past year, the company has underperformed compared to the broader market. Despite modest growth in net sales and operating profit, its profitability remains low, reflected in its valuation metrics.

Betta Pharmaceuticals Co., Ltd. saw a notable increase in stock performance on May 29, 2026, reaching an intraday high. The company has demonstrated resilience over the past week and month, despite facing longer-term challenges, with a market capitalization of CNY 20,911 million and a price-to-earnings ratio of 46.00.

Betta Pharmaceuticals Co., Ltd. saw a significant rise on March 27, 2026, contrasting with the modest gain of the China Shanghai Composite. The company has experienced mixed performance recently, with annual net sales growth of 12.42% but only a 5.21% increase in operating profit, indicating a complex financial outlook.

Betta Pharmaceuticals Co., Ltd. saw a 3.6% increase in stock performance today, reaching an intraday high of CNY 41.79. However, the company has faced declines over the past week, month, and year-to-date, with a market capitalization of CNY 18,971 million and a price-to-earnings ratio of 74.00.

Betta Pharmaceuticals Co., Ltd. saw a notable stock decline today, underperforming compared to the broader market. The company has faced significant challenges over the past year and five years, with declining profits and elevated valuation metrics, despite offering a modest dividend yield. Its market capitalization is CNY 18,971 million.

Betta Pharmaceuticals Co., Ltd. saw a significant daily increase, contrasting with the modest rise of the China Shanghai Composite. However, the company has struggled over the past year, with a notable decline in net profit and mixed financial metrics, indicating potential concerns about its long-term performance.

Betta Pharmaceuticals Co., Ltd. faced a significant decline in stock performance on March 3, 2026, with ongoing challenges reflected in its recent metrics. The company has experienced notable drops over various time frames, while its long-term growth indicators suggest a disconnect with current investor expectations amid a premium valuation.

Betta Pharmaceuticals Co., Ltd. faced notable market activity on October 15, 2025, with a significant decline in stock value. Despite recent short-term challenges, the company has shown strong annual performance, outperforming the China Shanghai Composite. Financial metrics reveal a market capitalization of CNY 27,699 million and a price-to-earnings ratio of 72.00.

Betta Pharmaceuticals Co., Ltd. faced a challenging trading day on October 14, 2025, with a notable stock decline. Despite recent downturns, the company has achieved a strong annual return and maintains a significant market capitalization, alongside a high price-to-earnings ratio and a modest dividend yield.

Betta Pharmaceuticals Co., Ltd. saw a significant decline in its stock today, contrasting with the broader market's performance. Despite recent losses, the company has demonstrated strong long-term growth, with notable increases in stock value over the past year and three years, alongside key financial metrics reflecting its industry standing.

Betta Pharmaceuticals Co., Ltd. saw a decline in its stock today, contrasting with a gain in the China Shanghai Composite. Despite recent fluctuations, the company has achieved significant annual growth and maintains a strong market capitalization, price-to-earnings ratio, and return on equity, reflecting its long-term resilience.